Post-pandemic, several deals have entered the healthcare M&A pipeline. LaingBuisson reports that advisers have appointed to help sell businesses in children’s services (Keys Group, Sandcastle Care and Priory Group), mental health (Huntercombe Group and Priory Group), private hospitals (Aspen Healthcare) and specialist care (Active Care Group). Competition and Markets Authority (CMA) intervention will be a…
The acquisition of neuro-rehabilitation provider, Christchurch Group, by Montreux Capital in December 2019 is a useful prompt for reviewing merger control risks in neuro-rehab services and wider adult specialist care. While the Competition and Markets Authority (CMA) has reviewed several mergers in the mental health sector in recent years (e.g. Acadia’s acquisition of Priory Group), neuro-rehab…
NHS mental health trusts could, according to a report in HSJ, face regulatory action for not reducing the time patients spend in units a long way from home (known as ‘out of area placements’). There is little to argue about with a policy that is aimed at ending by 2020/21 what are known in NHS-speak…
Guides, White Papers & Research
Buy-and-Build Strategies: Managing the risk of UK Competition and Markets Authority intervention
This paper draws on our experience as former competition regulators, and our research on buy-and-builds, to identify opportunities that can mitigate the risk of CMA intervention for these platforms.
It contains practical advice around:
- The likelihood of deals being called-in by the CMA
- Influencing the CMA’s view of a market
- How to best engage with the CMA
- Drivers of CMA review costs
Fill in your details to receive your copy:
We will never share your details with anyone.